Clene Submits New Drug Application To FDA For Accelerated Approvla Of CNM-Au8

Clene has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval for its drug CNM-Au8. The application is based on data related to neurofilament light chain biomarkers and clinical outcomes. This move is significant for the company's growth strategy and potential market impact.